Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration

Philip J. Rosenfeld, Andrew A. Moshfeghi, Carmen A. Puliafito

Research output: Contribution to journalArticlepeer-review

843 Scopus citations

Abstract

To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degeneration who was responding poorly to pegaptanib therapy, an intravitreal injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coherence tomography revealed resolution of the subretinal fluid, resulting in a normal-appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observed. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.

Original languageEnglish (US)
Pages (from-to)331-335
Number of pages5
JournalOphthalmic Surgery Lasers and Imaging
Volume36
Issue number4
DOIs
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint

Dive into the research topics of 'Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this